Get the Stockscreener App
18.37
4.67%
-0.90
After Hours:
18.37
Newamsterdam Pharma Company Nv stock is traded at $18.37, with a volume of 974.27K.
It is down -4.67% in the last 24 hours and up +15.83% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$19.27
Open:
$19.29
24h Volume:
974.27K
Relative Volume:
1.05
Market Cap:
$2.20B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-8.5442
EPS:
-2.15
Net Cash Flow:
$-141.24M
1W Performance:
-8.29%
1M Performance:
+15.83%
6M Performance:
-23.84%
1Y Performance:
-15.97%
1-Day Range:
$18.27
$19.82
1-Week Range:
$17.49
$20.91
52-Week Range:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
18.37 | 2.20B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
Barclays PLC Buys 9,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Needham & Company LLC Issues Pessimistic Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
NewAmsterdam Pharma Reports Q1 2025 Financial Results - TipRanks
NewAmsterdam Pharma Q1 Net Loss Narrows, Revenue Rises - marketscreener.com
NewAmsterdam Pharma Company NV reports results for the quarter ended March 31Earnings Summary - TradingView
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewswire
Ratios Revealed: Decoding NewAmsterdam Pharma Company NV (NAMS)’s Financial Health - DWinneX
Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $2.98M, vs. FactSet Est of $1.6M - marketscreener.com
NewAmsterdam Pharma Q1 2025 Financial Results and Corporate Update - TradingView
Envestnet Asset Management Inc. Sells 8,738 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Announces Late-Breaking Data from - GlobeNewswire
NewAmsterdam Pharma (NAMS) Reveals Promising Phase 3 Study Results for Obicetrapib | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Presents Promising Phase 3 Trial Data - TipRanks
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 - Stock Titan
Trend Tracker for (NAMS) - news.stocktradersdaily.com
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33 - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Expands Clinical Team with 11 New Hires, Awards $4M in Equity Grants - Stock Titan
Examining NewAmsterdam Pharma Company NV (NAMS) stock is warranted - uspostnews.com
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress - GlobeNewswire
Major Breakthrough: NewAmsterdam Reveals Multiple Phase 3 Trial Results for Novel Heart Drug - Stock Titan
Geode Capital Management LLC Raises Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
Legal & General Group Plc Acquires 4,556 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Invesco Ltd. Invests $3.87 Million in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by JPMorgan Chase & Co. - Defense World
A closer look at NewAmsterdam Pharma Company NV (NAMS)’s stock price trends - uspostnews.com
Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
(NAMSW) Trading Report - news.stocktradersdaily.com
11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey
Head to Head Survey: NewAmsterdam Pharma (NASDAQ:NAMS) vs. Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Is NewAmsterdam Pharma Company NV (NASDAQ: NAMS) A Good Investment Now? - Stocksregister
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares By Investing.com - Investing.com Canada
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors - The Manila Times
NewAmsterdam Pharma adds Adele Gulfo to its Board By Investing.com - Investing.com South Africa
Newamsterdam pharma COO Douglas Kling sells $1.65 million in shares - Investing.com Australia
NewAmsterdam Pharma adds Adele Gulfo to its Board - Investing.com
Blockbuster Drug Veteran Who Led $12B Pfizer Unit Joins NewAmsterdam Board Before Critical Launch - Stock Titan
Arrowstreet Capital Limited Partnership Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Sei Investments Co. Sells 14,456 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - Insider Monkey
KLP Kapitalforvaltning AS Purchases Shares of 6,000 NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low – Here’s Why - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Average Price Target from Analysts - Defense World
Where are the Opportunities in (NAMSW) - news.stocktradersdaily.com
NewAmsterdam Pharma Expands Team: 133,000 Shares Granted to Strategic New Hires - Stock Titan
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - MarketScreener
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):